The engraftment results showed that IL-17A treatment promoted Ph+ B-ALL progression (Fig. 2h and Supplementary Fig. 2d), as indicated by the increased infiltration of leukemia cells in the PB, BM, and spleen (Fig. 2i, j and Supplementary Fig. 2e), ultimately leading to a decreased overall survival rate of leukemia-engrafted mice (Fig. 2k). The gene discussed is IL17A; the disease is acute lymphoblastic leukemia.